Cognition Therapeutics, Inc. - Common Stock (NQ:CGTX)

1.105 +0.025 (+2.31%)

Streaming Delayed Price Updated: 11:11 AM EDT, Mar 17, 2026 Add to My Watchlist

Price and Volume

Volume	423,429
Open	1.100
Bid (Size)	1.100 (4,100)
Ask (Size)	1.110 (10,200)
Prev. Close	1.080
Today's Range	1.095 - 1.168
52wk Range	0.2223 - 3.830
Shares Outstanding	88,268,078
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026

Today 7:30 EDT

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis

March 02, 2026

We believe regulatory strategy expedites development of potential first treatment to address DLB psychosis

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Performance

YTD	-24.8%	-24.8%
1 Month	-1.3%	-1.3%
3 Month	-30.9%	-30.9%
6 Month	-28.2%	-28.2%
1 Year	+147.3%	+147.3%

More News

Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

February 05, 2026

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies

January 27, 2026

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy Bodies

January 06, 2026

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

December 03, 2025

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference

December 01, 2025

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer’s Disease

November 13, 2025

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs

November 06, 2025

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Here are the top movers in Monday's session. ↗

September 15, 2025

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

September 15, 2025

Via Benzinga

Which stocks are moving on Monday? ↗

September 15, 2025

Via Chartmill

These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025 ↗

September 03, 2025

Via The Motley Fool

Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)

September 02, 2025

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Wondering what's happening in today's pre-market session? ↗

August 28, 2025

Via Chartmill

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

August 28, 2025

Via Benzinga

Why Snowflake Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket ↗

August 28, 2025

Via Benzinga

Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock

August 27, 2025

From Cognition Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

August 26, 2025

Via Benzinga

The market is filled with gapping stocks in Monday's session. ↗

August 25, 2025

Via Chartmill

What's going on in today's session ↗

August 22, 2025

Via Chartmill

12 Health Care Stocks Moving In Friday's Intraday Session ↗

August 22, 2025

Via Benzinga

Friday's session: top gainers and losers ↗

August 22, 2025

Via Chartmill

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

August 14, 2025

Via Benzinga

Thursday's session: top gainers and losers ↗

August 14, 2025

Via Chartmill

Frequently Asked Questions

Is Cognition Therapeutics, Inc. - Common Stock publicly traded?

Yes, Cognition Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Cognition Therapeutics, Inc. - Common Stock trade on?

Cognition Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Cognition Therapeutics, Inc. - Common Stock?

The ticker symbol for Cognition Therapeutics, Inc. - Common Stock is CGTX on the Nasdaq Stock Market

What is the current price of Cognition Therapeutics, Inc. - Common Stock?

The current price of Cognition Therapeutics, Inc. - Common Stock is 1.105

When was Cognition Therapeutics, Inc. - Common Stock last traded?

The last trade of Cognition Therapeutics, Inc. - Common Stock was at 03/17/26 11:11 AM ET

What is the market capitalization of Cognition Therapeutics, Inc. - Common Stock?

The market capitalization of Cognition Therapeutics, Inc. - Common Stock is 97.54M

How many shares of Cognition Therapeutics, Inc. - Common Stock are outstanding?

Cognition Therapeutics, Inc. - Common Stock has 98M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.